Ernest Hamel Selected Research

Tubulin

6/2022	Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents.
10/2021	Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia.
1/2021	Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure-activity relationship, in vitro and in vivo evaluation as antitumor agents.
5/2020	Synthesis and Biological Evaluation of 2-Substituted Benzyl-/Phenylethylamino-4-amino-5-aroylthiazoles as Apoptosis-Inducing Anticancer Agents.
4/2020	Synthesis and Biological Evaluation of New Antitubulin Agents Containing 2-(3',4',5'-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine Scaffold.
1/2020	S-(4-Methoxyphenyl)-4-methoxybenzenesulfonothioate as a Promising Lead Compound for the Development of a Renal Carcinoma Agent.
1/2020	Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
1/2020	Design, Synthesis and In Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-diaryl-1H-pyrrol-3-yl)-2-oxo-N-(pyridin-3- yl)acetamide.
11/2019	Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors.
8/2019	Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ernest Hamel Research Topics

Disease

105	Neoplasms (Cancer) 06/2022 - 06/2002
6	Breast Neoplasms (Breast Cancer) 01/2021 - 12/2004
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2021 - 06/2009
4	Carcinoma (Carcinomatosis) 01/2021 - 06/2005
4	Leukemia 09/2014 - 06/2005
3	Glioblastoma (Glioblastoma Multiforme) 10/2021 - 11/2018
3	Hypoxia (Hypoxemia) 01/2020 - 06/2008
3	Prostatic Neoplasms (Prostate Cancer) 02/2014 - 08/2007
2	Glioma (Gliomas) 01/2021 - 01/2017
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 06/2019
2	Lymphoid Leukemia 10/2005 - 03/2004
1	Carcinogenesis 10/2021
1	Lymphoma (Lymphomas) 10/2020
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020
1	Blast Crisis (Blast Phase) 05/2017

Drug/Important Bio-Agent (IBA)

60	TubulinIBA 06/2022 - 10/2002
19	Colchicine FDA LinkGeneric 05/2018 - 01/2005
14	fosbretabulin (combretastatin A4)IBA 03/2021 - 06/2002
11	Phosphates (Orthophosphate)IBA 08/2020 - 06/2002
10	Antineoplastic Agents (Antineoplastics)IBA 05/2020 - 07/2005
10	ProdrugsIBA 01/2020 - 06/2005
9	Pharmaceutical PreparationsIBA 01/2021 - 06/2002
7	SaltsIBA 08/2019 - 03/2004
7	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2017 - 07/2002
7	Tubulin ModulatorsIBA 05/2015 - 06/2005
6	indoleIBA 12/2018 - 06/2009
6	Biological ProductsIBA 12/2015 - 06/2005
5	benzofuranIBA 04/2015 - 09/2008
5	benzothiopheneIBA 03/2013 - 05/2007
4	Growth InhibitorsIBA 05/2018 - 03/2004
4	StilbenesIBA 10/2005 - 06/2002
3	PyrrolesIBA 10/2021 - 08/2014
3	Imatinib Mesylate (Gleevec)FDA Link 10/2021 - 05/2017
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2008
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 08/2005
3	pyridineIBA 04/2020 - 10/2008
3	combretastatin A-1IBA 01/2020 - 07/2011
3	ChalconesIBA 08/2019 - 04/2009
3	furanIBA 04/2015 - 10/2011
3	combretastatinIBA 05/2014 - 05/2009
3	2-MethoxyestradiolIBA 06/2008 - 10/2002
3	AmidesIBA 08/2005 - 10/2002
2	Caspase 3 (Caspase-3)IBA 01/2021 - 01/2020
2	Phosphotransferases (Kinase)IBA 01/2021 - 03/2012
2	OxazolesIBA 10/2020 - 01/2017
2	ThiazolesIBA 05/2020 - 06/2012
2	ThiophenesIBA 04/2020 - 09/2014
2	EnzymesIBA 01/2020 - 01/2017
2	indibulinIBA 01/2020 - 06/2019
2	Oxidoreductases (Dehydrogenase)IBA 01/2020 - 01/2017
2	Cytostatic AgentsIBA 01/2017 - 05/2014
2	phenstatinIBA 01/2017 - 06/2002
2	Angiogenesis InhibitorsIBA 01/2017 - 05/2014
2	Antimitotic AgentsIBA 01/2017 - 08/2014
2	benzosubereneIBA 12/2016 - 06/2012
2	EstersIBA 11/2016 - 09/2011
2	Benzene (Benzole)IBA 04/2015 - 07/2010
2	Docetaxel (Taxotere)FDA Link 07/2014 - 05/2007
2	Sunitinib (Sutent)FDA Link 07/2014 - 05/2014
2	sulfamic acid (ammonium sulfamate)IBA 02/2014 - 01/2014
2	2- (3'- hydroxy- 4'- methoxyphenyl)- 3- (3'',4'',5''- trimethoxybenzoyl)- 6- methoxyindoleIBA 11/2013 - 09/2013
2	Phenol (Carbolic Acid)FDA Link 09/2013 - 06/2012
2	benzocycloheptapyridineIBA 03/2013 - 09/2008
2	FR 182877IBA 01/2012 - 08/2005
2	laulimalideIBA 08/2011 - 07/2002
2	Boronic AcidsIBA 01/2010 - 09/2005
2	Chalcone (Benzalacetophenone)IBA 01/2010 - 04/2009
2	ResveratrolIBA 09/2009 - 06/2002
2	SulfurIBA 05/2007 - 04/2006
2	AminesIBA 08/2005 - 02/2003
2	dolastatin 11IBA 07/2005 - 12/2002
2	lavendustin AIBA 04/2003 - 10/2002
1	pyrimidineIBA 06/2022
1	Aniline CompoundsIBA 06/2022
1	1-(2-chloroethyl)-1-nitrosourea (CNU)IBA 10/2021
1	Tyrosine Kinase InhibitorsIBA 10/2021
1	PalladiumIBA 03/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2021
1	Receptor-Interacting Protein Serine-Threonine KinasesIBA 01/2021
1	Taxoids (Taxanes)IBA 01/2021
1	Temozolomide (Temodar)FDA LinkGeneric 01/2021
1	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 01/2021
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	QuinazolinesIBA 01/2021
1	Heterocyclic Compounds (Compounds, Heterocyclic)IBA 01/2021
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2020
1	DisulfidesIBA 01/2020
1	NADPH-Ferrihemoprotein Reductase (Cytochrome P450 Reductase)IBA 01/2020
1	BuffersIBA 01/2020
1	nilotinib FDA Link 01/2020
1	Annexin A5IBA 01/2020
1	CarbazolesIBA 11/2018
1	compound 21IBA 01/2018
1	Oxygen (Dioxygen)IBA 01/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017
1	Pemetrexed (MTA)FDA Link 01/2017

Therapy/Procedure

7	Therapeutics 11/2018 - 09/2008
6	Drug Therapy (Chemotherapy) 01/2021 - 07/2002
1	Radiotherapy 01/2021